Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 12, 2024Biomedicine & PharmacotherapyOpen Access

Selective therapeutic efficacy of tyrosine kinase inhibitor sorafenib on the restoration of methylglyoxal-induced peritoneal fibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYu-Syuan WeiCWChing‐Ho WuSLShuei‐Liong Lin

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wei et al. (2024) studied this question.

synapsesocial.com/papers/68e650b4b6db6435875e13a7https://doi.org/10.1016/j.biopha.2024.116905
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sorafenib inhibits transforming growth factor β1-Mediated Epithelial-Mesenchymal Transition and apoptosis in mouse hepatocytes2011 · 99 citations
  2. 2Retinal glial activation in diabetic retinopathy: therapeutic impact of multikinase inhibition with sorafenib2025 · 4 citations
  3. 3Sorafenib and edaravone protect against renal fibrosis induced by unilateral ureteral obstruction via inhibition of oxidative stress, inflammation, and RIPK-3/MLKL pathway2024 · 10 citations
  4. 4Exploring the Inhibitory Effects of Compounds for the Treatment of Liver Fibrosis: A Computational and Microscopic Approach2026
  5. 5REACTIVE RETINAL GLIOSIS IN EXPERIMENTAL DIABETIC RETINOPATHY AND THE EFFECT OF INHIBITION OF CELLULAR PROTEIN KINASES2025